BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

956 related articles for article (PubMed ID: 24750853)

  • 21. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma.
    Kulik L; Vouche M; Koppe S; Lewandowski RJ; Mulcahy MF; Ganger D; Habib A; Karp J; Al-Saden P; Lacouture M; Cotliar J; Abecassis M; Baker T; Salem R
    J Hepatol; 2014 Aug; 61(2):309-17. PubMed ID: 24681342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
    Schmidt L; op den Winkel M; Fischer K; Straub G; Rauch B; Paprottka PM; Göke B; Kolligs FT
    Digestion; 2014; 90(4):219-28. PubMed ID: 25502689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
    Pecorelli A; Lenzi B; Gramenzi A; Garuti F; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Felder M; Morisco F; Gasbarrini A; Baroni GS; Foschi FG; Biasini E; Masotto A; Virdone R; Bernardi M; Trevisani F;
    Liver Int; 2017 Mar; 37(3):423-433. PubMed ID: 27566596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
    Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
    Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know.
    Kim YH; Kim DY
    Oncology; 2013; 84 Suppl 1():34-9. PubMed ID: 23428856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis.
    Martelletti C; Ricotti A; Gesualdo M; Carucci P; Gaia S; Rolle E; Burlone ME; Okolicsanyi S; Mattalia A; Pirisi M; Berchialla P; Tabone M
    J Dig Dis; 2021 Aug; 22(8):496-502. PubMed ID: 34189839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib.
    Lucà MG; Nani R; Schranz M; De Giorgio M; Iegri C; Agazzi R; Sala F; Virotta G; Sarti D; Conte G; Pinelli D; Nicora C; Colledan M; Sironi S; Fagiuoli S
    Future Oncol; 2018 Apr; 14(8):727-735. PubMed ID: 29578364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
    Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
    Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C.
    Wang JH; Kuo YH; Wang CC; Chen CL; Cheng YF; Hsu HC; Lu SN
    Dig Liver Dis; 2013 Jun; 45(6):510-5. PubMed ID: 23218990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
    Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation.
    Shouval D
    J Hepatol; 2014 Aug; 61(2):190-2. PubMed ID: 24845608
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
    Kim GA; Shim JH; Yoon SM; Jung J; Kim JH; Ryu MH; Ryoo BY; Kang YK; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    J Vasc Interv Radiol; 2015 Mar; 26(3):320-9.e6. PubMed ID: 25612807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.